Germany Medical Device Reimbursement Strategy
German Medical Device Reimbursement Strategy & Market Access
How do medical devices obtain reimbursement in Germany? Achieving market access requires a dual strategy aligned with either inpatient (G-DRG) or outpatient (EBM/GOÄ) sectors. Manufacturers must map technologies to valid OPS procedure codes, secure specialized innovation add-on funding like NUB applications, utilize conditional reimbursement frameworks via the Joint Federal Committee (G-BA), or leverage the fast-track DiGA pathway for digital health software.
The purpose of this step is to understand the current reimbursement environment in Germany, relevant for your medical device. To do so, we will:
- Clarify the relevant type of coding systems (OPS, EBM or GOÄ), coding under the Digital Health Applications (DiGA) pathway (now supporting Class I, IIa, and IIb digital health applications), coverage policies, limitations and guidelines, relevant type of payment mechanisms (G-DRG, EBM or GOÄ) and payment rates, applicable for the specific device or to any comparable products.
- Locate any specific reimbursement mechanisms that could be utilized by the device, as-is, or recommend on whether new mechanisms will have to be developed and if so, which mechanisms (e.g., a new EBM or GOÄ code, NUB reimbursement or an application for inclusion in the Medical Aids Directory).
- Identify the main decision makers, lay out the typical path towards obtaining statutory (GKV) or private (PKV) reimbursement, including milestones and typical timelines and provide an initial reimbursement strategy for the device in Germany.
Partnering with a German Medical Device Reimbursement Consultant for Evidence Planning
According to the conclusions in the Reimbursement Landscape, we devise the plan for developing the required evidence for German decision makers, such as the Joint Federal Committee (G-BA), the Agency for the Hospital Payment System (InEK) or the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband). This includes the development of:
- Value Story: Puts forward the claims for clinical and economic benefits associated with the use of the new device in the eyes of the relevant decision makers (healthcare providers, German sickness funds) and would serve as the basis for the Economic Model.
- Economic Model: Highlights the economic benefits of the new device from the perspective of German decision makers. May identify specific outcomes data that should be added to future clinical study protocols.
- Clinical Data: Recommendations for adjustments and modifications of any planned clinical studies in order to generate the required reimbursement-related evidence for decision makers.
- Decision Makers' Feedback: Conduct interviews with the identified German decision makers to obtain their feedback regarding the developed value story, the economic model and the reimbursement aspects of the planned clinical study.
Strategic Case Profile: Inpatient Innovation Pathway Execution
Navigating the German market requires matching a novel technology to the precise operational realities of German hospitals. Below is a strategic profile demonstrating how an advanced, breakthrough hospital technology bypasses standard G-DRG limitations:
| Strategic Element | Execution Plan & Pathways |
|---|---|
| Technology Profile | High-cost, single-use inpatient ablation catheter providing superior outcomes over baseline surgery but exceeding standard G-DRG flat-rate allowances. |
| Coding Alignment | Identification and mapping to an existing sub-code within the OPS (Operationen und Prozedurenschlüssel) system, or preparing a formal submission to BfArM for a new structural tracking code. |
| Funding Mechanism | Leveraging the NUB (Neue Untersuchungs und Behandlungsmethoden) pathway. Partnering with pioneer German clinics to submit coordinated "Status 1" funding applications to InEK before the strict October 31st annual deadline. |
| Evidence Framework | Compiling a targeted clinical dossier mapping localized economic benefits (e.g., reduced ICU stay durations) to satisfy direct scrutiny from the Joint Federal Committee (G-BA) and individual statutory sickness funds (GKV). |
Market Access Implementation and Germany Reimbursement Strategy Execution
Depending upon the existence, or the lack of, applicable reimbursement mechanisms (as identified in the Reimbursement Landscape step), we will conduct the following activities:
- Billing Guide: Develop a set of instructions guiding physicians and other healthcare providers how to obtain reimbursement following the use of the new device.
- Reimbursement Applications: Work with the relevant medical societies to apply for new reimbursement mechanisms, such as OPS, EBM or GOÄ codes, NUB reimbursement or inclusion in the German Medical Aids Directory.
- Pilot Projects: Initiate pilot projects and selective contracts with local German sickness funds.
- Other Funding Options: Apply for other or interim funding options such as Conditional Coverage or the German Innovation Fund.
Germany Reimbursement FAQs
How long does medical device reimbursement take in Germany?
In 2026, timelines typically range from 6 to 24 months. Fast-track pathways like DiGA (90 days) exist, while inpatient NUB applications follow a strict annual cycle (October 31st deadline).
Which reimbursement pathways exist in Germany?
Pathways include OPS (procedure codes), EBM (ambulatory), GOÄ (private), NUB (innovation funding), and DiGA for digital health apps, now including higher-risk Class IIb devices.
Need Concrete Market Access Support?
Securing coverage and coding is the most critical step of your commercialization timeline. Our team maps global reimbursement pathways directly to your business goals.